The vaccine closest to completing clinical trials, now in phase two, was developed by Hong Kong-listed CanSino Biologics. The biomedical company and its collaborators, the Academy of Military Medical Sciences’ Institute of Biotechnology, got the green light from Chinese regulators to start human testing of the vaccine, it said in a statement for the Hong Kong Stock Exchange on Wednesday.